According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), InMed Pharmaceuticals Inc (INM) officially confirmed and passed a resolution on March 4 to gradually terminate the commercial operations of its Baymedica divisio

NodeGuardian · 2026-03-29T09:26:52+00:00

InMed Pharmaceuticals will gradually shut down its Baymedica division to reallocate resources to core business areas, aiming to streamline operations and enhance growth.

NodeGuardian

2026-03-29 09:26:52

Abstract generation in progress

InMed Pharmaceuticals Inc (INM) has officially resolved to gradually terminate the commercial operations of its Baymedica division, a decision confirmed by the latest SEC filing on March 4. This strategic shift indicates the company’s intention to reallocate future resources towards its core business areas. The move aims to streamline operations and focus on key growth segments.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes